You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBrimonidine
Accession NumberDB00484  (APRD00034)
TypeSmall Molecule
GroupsApproved
DescriptionBrimonidine is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. [Wikipedia] A topical gel formulation, marketed under the name Mirvaso, was FDA approved on August 2013 for the treatment of rosacea.
Structure
Thumb
Synonyms
5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline
Brimonidina
Brimonidine
Brimonidinum
Bromoxidine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlphaganLiquid0.2 %OphthalmicAllergan Inc1997-12-02Not applicableCanada
Alphagan PSolution / drops1.5 mg/mLOphthalmicAllergan, Inc.2001-07-10Not applicableUs
Alphagan PSolution / drops1 mg/mLOphthalmicAllergan, Inc.2006-01-25Not applicableUs
Alphagan PSolution / drops1 mg/mLOphthalmicPhysicians Total Care, Inc.2013-03-08Not applicableUs
Alphagan PSolution0.15 %OphthalmicAllergan Inc2003-11-05Not applicableCanada
Alphagan PSolution / drops1.5 mg/mLOphthalmicPhysicians Total Care, Inc.2002-10-16Not applicableUs
BrimonidineSolution0.2 %OphthalmicPharmascience IncNot applicableNot applicableCanada
Brimonidine OphthalmicSolution0.2 %OphthalmicPharmel IncNot applicableNot applicableCanada
Brimonidine PSolution0.15 %OphthalmicAa Pharma Inc2008-07-15Not applicableCanada
Brimonidine TartrateSolution1.5 mg/mLOphthalmicPhysicians Total Care, Inc.2009-12-22Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicPacific Pharma, Inc.2003-04-10Not applicableUs
Brimonidine TartrateSolution1.5 mg/mLOphthalmicSandoz Inc2010-10-02Not applicableUs
Brimonidine Tartrate Ophthalmic Solution 0.2%Solution0.2 %OphthalmicAlcon Canada IncNot applicableNot applicableCanada
Dom-brimonidineSolution0.2 %OphthalmicDominion PharmacalNot applicableNot applicableCanada
Jamp-brimonidineSolution0.2 %OphthalmicJamp Pharma CorporationNot applicableNot applicableCanada
MirvasoGel3 mg/gCutaneousGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneousGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneousGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneousGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneousGalderma International2014-02-21Not applicableEu
MirvasoGel3 mg/gCutaneousGalderma International2014-02-21Not applicableEu
MirvasoGel5 mg/gTopicalGalderma Laboratories, L.P.2013-08-23Not applicableUs
OnrelteaGel0.33 %TopicalGalderma Canada Inc2014-03-24Not applicableCanada
PMS-brimonidineSolution0.2 %OphthalmicPharmascience Inc2002-08-13Not applicableCanada
Ratio-brimonidineSolution0.2 %OphthalmicTeva Canada Limited2002-07-10Not applicableCanada
Sandoz BrimonidineSolution0.2 %OphthalmicSandoz Canada Incorporated2008-02-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-brimonidineSolution0.2 %OphthalmicApotex Inc2005-06-02Not applicableCanada
BrimonidineSolution / drops2 mg/mLOphthalmicAkorn, Inc.2006-09-07Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicRegimed Medical2016-01-05Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicSTAT Rx USA LLC2003-05-28Not applicableUs
Brimonidine TartrateSolution2 mg/mLOphthalmicSandoz Inc2003-09-17Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mgOphthalmicOsmotica Pharmaceutical Corp.2015-01-01Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicBausch & Lomb Incorporated2003-05-28Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicREMEDYREPACK INC.2013-06-24Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicA S Medication Solutions2003-05-28Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicPhysicians Total Care, Inc.2011-07-25Not applicableUs
Brimonidine Tartrate Ophthalmic Solution, 0.2%Solution / drops2 mg/mLOphthalmicWestminster Pharmaceuticals, Llc2015-09-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Apo-brimonidine-timopApotex Inc
CombiganPhysicians Total Care, Inc.
SimbrinzaAlcon Laboratories, Inc.
Salts
Name/CASStructureProperties
Brimonidine Tartrate
70359-46-5
Thumb
  • InChI Key: QZHBYNSSDLTCRG-LREBCSMRSA-N
  • Monoisotopic Mass: 441.028395916
  • Average Mass: 442.221
DBSALT000195
Categories
UNIIE6GNX3HHTE
CAS number59803-98-4
WeightAverage: 292.135
Monoisotopic: 291.011957992
Chemical FormulaC11H10BrN5
InChI KeyXYLJNLCSTIOKRM-UHFFFAOYSA-N
InChI
InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
IUPAC Name
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
SMILES
BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Pharmacology
IndicationThe ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older.
Structured Indications
PharmacodynamicsBrimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Mechanism of actionBrimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinyes
agonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinyes
agonist
HumanP18825 details
Related Articles
AbsorptionMinimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized primarily by the liver.

SubstrateEnzymesProduct
Brimonidine
2-oxobrimonidineDetails
Brimonidine
3-oxobrimonidine Details
Route of eliminationUrinary excretion is the major route of elimination of the drug and its metabolites.
Half life2 hours [ophthalmic solution]
ClearanceNot Available
ToxicityOral LD50 is 50 mg/kg in mice and 100 mg/kg in rats. Common adverse reactions of the topical gel formulation include erythema, flushing, skin burning sensation, and contact dermatitis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Brimonidine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,1,1,2 TetrafluoroethaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brimonidine.Experimental
7-NitroindazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Brimonidine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Brimonidine.Experimental
AcebutololBrimonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcebutololBrimonidine may increase the antihypertensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Brimonidine.Approved, Vet Approved
AcepromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brimonidine.Approved
AceprometazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Brimonidine.Investigational
adipiplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brimonidine.Approved, Investigational
AgomelatineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brimonidine.Vet Approved
AlfaxaloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Brimonidine.Approved, Illicit
AlfentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Brimonidine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Brimonidine is combined with Aliskiren.Approved, Investigational
AliskirenBrimonidine may increase the antihypertensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Brimonidine.Experimental, Illicit
AlphacetylmethadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brimonidine.Approved, Illicit, Investigational
AlprazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AlprenololBrimonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AlprenololBrimonidine may increase the antihypertensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanBrimonidine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmbrisentanBrimonidine may increase the antihypertensive activities of Ambrisentan.Approved, Investigational
AmifostineBrimonidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Brimonidine.Illicit, Withdrawn
AmineptineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brimonidine.Approved, Investigational
AmisulprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Brimonidine.Approved
AmitriptylineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amitriptyline.Approved
AmitriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Brimonidine.Approved
AmlodipineBrimonidine may increase the antihypertensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brimonidine.Approved, Illicit
AmobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amoxapine.Approved
AmoxapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Brimonidine.Experimental
AmperozideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amyl Nitrite.Approved
Aop200704Brimonidine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Brimonidine.Approved, Investigational
AripiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArotinololBrimonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Brimonidine.Approved
ArticaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Brimonidine.Approved
AsenapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtenololBrimonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtenololBrimonidine may increase the antihypertensive activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Brimonidine.Vet Approved
AzaperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Vet Approved
AzelastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Brimonidine.Approved
BaclofenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Brimonidine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Brimonidine.Illicit
BarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Barnidipine.Approved
BefunololBrimonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Benazepril.Approved, Investigational
BenazeprilBrimonidine may increase the antihypertensive activities of Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Brimonidine.Approved
BendroflumethiazideBrimonidine may increase the antihypertensive activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Brimonidine.Withdrawn
BenmoxinBenmoxin may increase the hypotensive activities of Brimonidine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Brimonidine is combined with Benperidol.Investigational
BenperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Brimonidine.Approved
BenzocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brimonidine.Approved
Benzyl alcoholBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineBrimonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBrimonidine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BepridilBrimonidine may increase the antihypertensive activities of Bepridil.Approved, Withdrawn
BetaxololBrimonidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BetaxololBrimonidine may increase the antihypertensive activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Brimonidine.Approved
BethanidineBrimonidine may increase the antihypertensive activities of Bethanidine.Approved
BevantololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BimatoprostBrimonidine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BimatoprostBrimonidine may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
BisoprololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BisoprololBrimonidine may increase the antihypertensive activities of Bisoprolol.Approved
BopindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bortezomib.Approved, Investigational
BosentanBrimonidine may increase the hypotensive activities of Bosentan.Approved, Investigational
BosentanBrimonidine may increase the antihypertensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bretylium.Approved
BretyliumBrimonidine may increase the antihypertensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brimonidine is combined with Brexpiprazole.Approved
BrexpiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brimonidine.Approved, Illicit
BromazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromocriptineBromocriptine may increase the hypertensive activities of Brimonidine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Brompheniramine.Approved
BrompheniramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Brimonidine.Approved, Withdrawn
BrotizolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Withdrawn
BucindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolBrimonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brimonidine.Approved, Investigational
BupivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BupranololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BupranololBrimonidine may increase the antihypertensive activities of Bupranolol.Approved
BuprenorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Brimonidine.Approved, Investigational
BuspironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brimonidine.Approved, Illicit
ButabarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Brimonidine.Vet Approved
ButacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Brimonidine.Approved, Illicit
ButalbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Brimonidine.Approved
ButambenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Brimonidine.Approved, Illicit
ButethalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brimonidine.Approved, Illicit, Vet Approved
ButorphanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive activities of Brimonidine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Candesartan.Approved
CandesartanBrimonidine may increase the antihypertensive activities of Candesartan.Approved
CandoxatrilBrimonidine may increase the hypotensive activities of Candoxatril.Experimental
CandoxatrilBrimonidine may increase the antihypertensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Captopril.Approved
CaptoprilBrimonidine may increase the antihypertensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brimonidine.Approved, Investigational
CarbamazepineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Carbinoxamine.Approved
CarbinoxamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Brimonidine.Illicit, Vet Approved
CarfentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brimonidine.Approved
CarisoprodolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Brimonidine.Withdrawn
CaroxazoneCaroxazone may increase the hypotensive activities of Brimonidine.Withdrawn
CarteololBrimonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarteololBrimonidine may increase the antihypertensive activities of Carteolol.Approved
CarvedilolBrimonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CarvedilolBrimonidine may increase the antihypertensive activities of Carvedilol.Approved, Investigational
CeliprololBrimonidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeliprololBrimonidine may increase the antihypertensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brimonidine.Approved
CetirizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brimonidine.Approved, Illicit, Vet Approved
Chloral hydrateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brimonidine.Approved, Illicit
ChlordiazepoxideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Brimonidine.Approved, Withdrawn
ChlormezanoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brimonidine.Approved
ChloroprocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Chlorothiazide.Approved, Vet Approved
ChlorothiazideBrimonidine may increase the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Chlorphenamine.Approved
ChlorphenamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brimonidine.Approved, Vet Approved
ChlorpromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brimonidine.Approved, Withdrawn
ChlorprothixeneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Brimonidine.Approved
ChlorthalidoneBrimonidine may increase the antihypertensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brimonidine.Approved
ChlorzoxazoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Cilazapril.Approved
CilazaprilBrimonidine may increase the antihypertensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Cilnidipine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brimonidine.Approved, Vet Approved
CinchocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Brimonidine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Brimonidine.Approved
ClemastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clidinium.Approved
ClidiniumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Brimonidine.Approved, Illicit
ClobazamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Brimonidine.Investigational
clomethiazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Brimonidine.Approved, Vet Approved
ClomipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Clomipramine.Approved, Vet Approved
ClomipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clonazepam.Approved, Illicit
ClonazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clonidine.Approved
ClonidineBrimonidine may increase the antihypertensive activities of Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brimonidine.Approved, Illicit
ClorazepateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Brimonidine.Approved
ClozapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Brimonidine.Approved, Illicit
CocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Brimonidine.Approved, Illicit
CodeineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Conivaptan.Approved, Investigational
CryptenamineBrimonidine may increase the hypotensive activities of Cryptenamine.Approved
CryptenamineBrimonidine may increase the antihypertensive activities of Cryptenamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Cyclizine.Approved
CyclizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Brimonidine.Approved
CyclobenzaprineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Cyclobenzaprine.Approved
CyclobenzaprineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclothiazideBrimonidine may increase the hypotensive activities of Cyclothiazide.Approved
CyclothiazideBrimonidine may increase the antihypertensive activities of Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brimonidine.Approved
CyproheptadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dantrolene.Approved
DantroleneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brimonidine.Approved
DapiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapoxetine.Investigational
DebrisoquinBrimonidine may increase the hypotensive activities of Debrisoquin.Approved
DebrisoquinBrimonidine may increase the antihypertensive activities of Debrisoquin.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Brimonidine.Investigational
deramciclaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Investigational
DeserpidineBrimonidine may increase the hypotensive activities of Deserpidine.Approved
DeserpidineBrimonidine may increase the antihypertensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Brimonidine.Approved
DesfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Brimonidine.Approved
DesipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Desipramine.Approved
DesipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Desloratadine.Approved, Investigational
DesloratadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Brimonidine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Brimonidine.Vet Approved
DetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brimonidine.Approved
DexbrompheniramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dexmedetomidine.Approved, Vet Approved
DexmedetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brimonidine.Experimental, Illicit
DextromoramideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brimonidine.Approved, Illicit, Withdrawn
DextropropoxypheneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Brimonidine.Approved
DezocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Brimonidine.Approved, Illicit, Vet Approved
DiazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Brimonidine.Approved
DiazoxideBrimonidine may increase the antihypertensive activities of Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Diclofenamide.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Difenoxin.Approved, Illicit
DifenoxinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DigoxinBrimonidine may increase the bradycardic activities of Digoxin.Approved
DihydralazineBrimonidine may increase the hypotensive activities of Dihydralazine.Investigational
DihydralazineBrimonidine may increase the antihypertensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brimonidine.Approved, Illicit
DihydrocodeineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Brimonidine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brimonidine.Experimental, Illicit
DihydroetorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brimonidine.Experimental, Illicit
DihydromorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Brimonidine.Approved
DiltiazemBrimonidine may increase the antihypertensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dimenhydrinate.Approved
DimenhydrinateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brimonidine.Approved
DiphenhydramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brimonidine.Approved, Illicit
DiphenoxylateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Brimonidine.Vet Approved
DoramectinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DorzolamideBrimonidine may increase the hypotensive activities of Dorzolamide.Approved
DorzolamideBrimonidine may increase the antihypertensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Brimonidine.Approved
DosulepinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Doxazosin.Approved
DoxazosinBrimonidine may increase the antihypertensive activities of Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Brimonidine.Approved
DoxepinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Doxepin.Approved
DoxepinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Brimonidine.Investigational
DPDPEBrimonidine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Brimonidine.Experimental, Illicit
DrotebanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineBrimonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brimonidine.Approved
DyclonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Brimonidine.Experimental, Illicit
EcgonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Brimonidine.Experimental
ECGONINE METHYL ESTERBrimonidine may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ecopipam.Investigational
EcopipamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Brimonidine is combined with Efavirenz.Approved, Investigational
EfavirenzBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfonidipineBrimonidine may increase the hypotensive activities of Efonidipine.Approved
EfonidipineBrimonidine may increase the antihypertensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Enalapril.Approved, Vet Approved
EnalaprilBrimonidine may increase the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBrimonidine may increase the hypotensive activities of Enalaprilat.Approved
EnalaprilatBrimonidine may increase the antihypertensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Brimonidine.Approved, Vet Approved
EnfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Brimonidine is combined with Entacapone.Approved, Investigational
EntacaponeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Eplerenone.Approved
EpoprostenolBrimonidine may increase the hypotensive activities of Epoprostenol.Approved
EpoprostenolBrimonidine may increase the antihypertensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Eprosartan.Approved
EprosartanBrimonidine may increase the antihypertensive activities of Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Brimonidine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Brimonidine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Brimonidine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Brimonidine.Investigational
EsmirtazapineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Esmirtazapine.Investigational
EsmololBrimonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Brimonidine.Approved, Illicit
EstazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brimonidine.Approved
EszopicloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etacrynic acid.Approved
EthanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brimonidine.Approved, Illicit, Withdrawn
EthchlorvynolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ethosuximide.Approved
EthosuximideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ethotoin.Approved
EthotoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brimonidine.Withdrawn
Ethyl carbamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brimonidine.Approved, Illicit
Ethyl loflazepateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brimonidine.Approved, Illicit
EthylmorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Brimonidine.Approved
EtidocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Brimonidine.Withdrawn
EtifoxineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Brimonidine.Approved
EtizolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Brimonidine.Approved
EtomidateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brimonidine.Illicit, Vet Approved
EtorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ezogabine.Approved
EzogabineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Felbamate.Approved
FelbamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Felodipine.Approved, Investigational
FelodipineBrimonidine may increase the antihypertensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brimonidine.Approved, Illicit, Withdrawn
FencamfamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamBrimonidine may increase the hypotensive activities of Fenoldopam.Approved
FenoldopamBrimonidine may increase the antihypertensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brimonidine.Approved, Illicit, Investigational, Vet Approved
FentanylBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fexofenadine.Approved
FexofenadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Flibanserin.Approved
FlibanserinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brimonidine.Approved, Illicit
FludiazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Flunarizine.Approved
FlunarizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brimonidine.Approved, Illicit
FlunitrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brimonidine.Approved, Withdrawn
FlupentixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brimonidine.Approved
FluphenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brimonidine.Approved, Illicit
FlurazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brimonidine.Approved
FluspirileneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluticasone Propionate.Approved
Fluticasone PropionateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brimonidine.Approved, Investigational
FluvoxamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fosinopril.Approved
FosinoprilBrimonidine may increase the antihypertensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fosphenytoin.Approved
FosphenytoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brimonidine.Approved, Illicit
FospropofolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.Approved, Vet Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Brimonidine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brimonidine.Approved, Investigational
GabapentinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Brimonidine is combined with gabapentin enacarbil.Approved
gabapentin enacarbilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Brimonidine.Approved, Illicit
Gamma Hydroxybutyric AcidBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Brimonidine is combined with Gepirone.Investigational
GepironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Brimonidine.Approved, Illicit
GlutethimideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GuanabenzBrimonidine may increase the hypotensive activities of Guanabenz.Approved
GuanabenzBrimonidine may increase the antihypertensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Brimonidine.Approved
GuanadrelBrimonidine may increase the antihypertensive activities of Guanadrel.Approved
GuanethidineBrimonidine may increase the hypotensive activities of Guanethidine.Approved
GuanethidineBrimonidine may increase the antihypertensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Guanfacine.Approved, Investigational
GuanfacineBrimonidine may increase the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Brimonidine.Approved, Illicit, Withdrawn
HalazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brimonidine.Approved
HaloperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Brimonidine.Approved, Vet Approved
HalothaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Brimonidine.Approved, Illicit
HeroinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit
HexamethoniumBrimonidine may increase the hypotensive activities of Hexamethonium.Experimental
HexamethoniumBrimonidine may increase the antihypertensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brimonidine.Approved
HexobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Brimonidine.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Brimonidine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Brimonidine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Hydralazine.Approved
HydralazineBrimonidine may increase the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrochlorothiazideBrimonidine may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideBrimonidine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydroflumethiazideBrimonidine may increase the antihypertensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brimonidine.Approved, Illicit
HydromorphoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Iloperidone.Approved
IloperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Brimonidine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Imidapril.Investigational
ImidaprilBrimonidine may increase the antihypertensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Brimonidine.Approved
ImipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Imipramine.Approved
ImipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indapamide.Approved
IndapamideBrimonidine may increase the antihypertensive activities of Indapamide.Approved
IndenololBrimonidine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndenololBrimonidine may increase the antihypertensive activities of Indenolol.Withdrawn
IndoraminBrimonidine may increase the hypotensive activities of Indoramin.Withdrawn
IndoraminBrimonidine may increase the antihypertensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Brimonidine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Brimonidine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Brimonidine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Brimonidine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Brimonidine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Irbesartan.Approved, Investigational
IrbesartanBrimonidine may increase the antihypertensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brimonidine.Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Brimonidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Brimonidine.Approved, Vet Approved
IsofluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Brimonidine.Approved
IsradipineBrimonidine may increase the antihypertensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brimonidine.Approved, Vet Approved
KetamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetanserinBrimonidine may increase the hypotensive activities of Ketanserin.Investigational
KetanserinBrimonidine may increase the antihypertensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brimonidine.Approved
KetazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brimonidine.Approved
KetobemidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
LabetalolBrimonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LabetalolBrimonidine may increase the antihypertensive activities of Labetalol.Approved
LacidipineBrimonidine may increase the hypotensive activities of Lacidipine.Approved
LacidipineBrimonidine may increase the antihypertensive activities of Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Lamotrigine.Approved, Investigational
LamotrigineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LatanoprostBrimonidine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LatanoprostBrimonidine may increase the antihypertensive activities of Latanoprost.Approved, Investigational
LercanidipineBrimonidine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LercanidipineBrimonidine may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levetiracetam.Approved, Investigational
LevetiracetamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Brimonidine.Approved
LevobupivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levocabastine.Approved
LevocabastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levocetirizine.Approved
LevocetirizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaBrimonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevodopaBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brimonidine.Approved
Levomethadyl AcetateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Brimonidine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brimonidine.Approved
LevorphanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brimonidine.Approved, Vet Approved
LidocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Lisinopril.Approved, Investigational
LisinoprilBrimonidine may increase the antihypertensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Brimonidine.Approved
LithiumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Brimonidine.Illicit
LofentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LofexidineBrimonidine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LofexidineBrimonidine may increase the antihypertensive activities of Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Brimonidine.Approved
LoratadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brimonidine.Approved
LorazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Losartan.Approved
LosartanBrimonidine may increase the antihypertensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brimonidine.Approved
LoxapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Brimonidine.Investigational
Lu AA21004Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brimonidine.Approved
LurasidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
MacitentanBrimonidine may increase the hypotensive activities of Macitentan.Approved
MacitentanBrimonidine may increase the antihypertensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Vet Approved
ManidipineBrimonidine may increase the hypotensive activities of Manidipine.Approved
ManidipineBrimonidine may increase the antihypertensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Maprotiline.Approved
MaprotilineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Brimonidine.Withdrawn
MebanazineMebanazine may increase the hypotensive activities of Brimonidine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mecamylamine.Approved
MecamylamineBrimonidine may increase the antihypertensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Meclizine.Approved
MeclizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Brimonidine.Vet Approved
MedetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Brimonidine.Approved, Nutraceutical, Vet Approved
MelatoninBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Brimonidine.Approved
MelperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brimonidine.Approved, Vet Approved
MepivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brimonidine.Approved, Illicit
MeprobamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brimonidine.Approved
MesoridazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Metaxalone.Approved
MetaxaloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Brimonidine.Approved
MethadoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Brimonidine.Approved, Illicit
Methadyl AcetateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brimonidine.Withdrawn
MethapyrileneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brimonidine.Illicit, Withdrawn
MethaqualoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brimonidine.Approved, Vet Approved
MethocarbamolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Brimonidine.Approved
MethohexitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brimonidine.Approved, Vet Approved
MethoxyfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methsuximide.Approved
MethsuximideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methyldopa.Approved
MethyldopaBrimonidine may increase the antihypertensive activities of Methyldopa.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Brimonidine.Investigational
Methylene blueMethylene blue may increase the hypotensive activities of Brimonidine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Brimonidine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brimonidine.Approved
MethylphenobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Brimonidine is combined with Metipranolol.Approved
MetipranololBrimonidine may increase the antihypertensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Metolazone.Approved
MetolazoneBrimonidine may increase the antihypertensive activities of Metolazone.Approved
MetoprololBrimonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetoprololBrimonidine may increase the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineBrimonidine may increase the sedative activities of Metyrosine.Approved
MetyrosineBrimonidine may increase the antihypertensive activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mianserin.Approved
MibefradilBrimonidine may increase the hypotensive activities of Mibefradil.Withdrawn
MibefradilBrimonidine may increase the antihypertensive activities of Mibefradil.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brimonidine.Approved, Illicit
MidazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MilnacipranMilnacipran may increase the tachycardic activities of Brimonidine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Brimonidine.Approved
MinaprineMinaprine may increase the hypotensive activities of Brimonidine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Brimonidine.Approved
MinoxidilBrimonidine may increase the antihypertensive activities of Minoxidil.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Brimonidine.Approved
MirtazapineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mirtazapine.Approved
MirtazapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brimonidine.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Brimonidine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Moexipril.Approved
MoexiprilBrimonidine may increase the antihypertensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Brimonidine.Approved
MolindoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Brimonidine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Brimonidine.Approved, Investigational
MorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxonidineBrimonidine may increase the hypotensive activities of Moxonidine.Approved
MoxonidineBrimonidine may increase the antihypertensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Investigational
NadololBrimonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NadololBrimonidine may increase the antihypertensive activities of Nadolol.Approved
NaftopidilBrimonidine may increase the hypotensive activities of Naftopidil.Investigational
NaftopidilBrimonidine may increase the antihypertensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brimonidine.Approved
NalbuphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nebivolol.Approved, Investigational
NebivololBrimonidine may increase the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nesiritide.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Brimonidine.Withdrawn
NialamideNialamide may increase the hypotensive activities of Brimonidine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nicardipine.Approved
NicardipineBrimonidine may increase the antihypertensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Brimonidine.Approved
NicorandilBrimonidine may increase the antihypertensive activities of Nicorandil.Approved
NifedipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nifedipine.Approved
NiguldipineBrimonidine may increase the hypotensive activities of Niguldipine.Experimental
NiguldipineBrimonidine may increase the antihypertensive activities of Niguldipine.Experimental
NilvadipineBrimonidine may increase the hypotensive activities of Nilvadipine.Approved
NilvadipineBrimonidine may increase the antihypertensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Brimonidine.Approved
NimodipineBrimonidine may increase the antihypertensive activities of Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Brimonidine.Approved
NisoldipineBrimonidine may increase the antihypertensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brimonidine.Approved
NitrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineBrimonidine may increase the hypotensive activities of Nitrendipine.Approved
NitrendipineBrimonidine may increase the antihypertensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Brimonidine.Approved
NitroprussideBrimonidine may increase the antihypertensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Brimonidine.Approved, Vet Approved
Nitrous oxideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Brimonidine.Approved, Illicit
NormethadoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Brimonidine.Approved
NortriptylineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Nortriptyline.Approved
NortriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
ObinutuzumabBrimonidine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Brimonidine.Withdrawn
OctamoxinOctamoxin may increase the hypotensive activities of Brimonidine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brimonidine.Approved, Investigational
OlanzapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Brimonidine.Approved, Investigational
OlmesartanBrimonidine may increase the antihypertensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Olopatadine.Approved
OlopatadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OmapatrilatBrimonidine may increase the hypotensive activities of Omapatrilat.Investigational
OmapatrilatBrimonidine may increase the antihypertensive activities of Omapatrilat.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brimonidine.Approved
OndansetronBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Brimonidine.Investigational
OpipramolThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Brimonidine.Approved, Illicit
OpiumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Brimonidine.Investigational
OsanetantBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brimonidine.Approved
OxazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Oxetacaine.Investigational
OxetacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.Investigational
OxprenololBrimonidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxprenololBrimonidine may increase the antihypertensive activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brimonidine.Approved
OxybuprocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brimonidine.Approved, Illicit, Investigational
OxycodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brimonidine.Approved, Investigational, Vet Approved
OxymorphoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brimonidine.Approved
PaliperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Papaverine.Approved
ParaldehydeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Brimonidine.Approved
PargylinePargyline may increase the hypotensive activities of Brimonidine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.Approved, Investigational
PenbutololBrimonidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenbutololBrimonidine may increase the antihypertensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brimonidine.Approved, Vet Approved
PentazocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brimonidine.Approved, Vet Approved
PentobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PentoliniumBrimonidine may increase the hypotensive activities of Pentolinium.Approved
PentoliniumBrimonidine may increase the antihypertensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Brimonidine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Perazine.Investigational
PerazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Perindopril.Approved
PerindoprilBrimonidine may increase the antihypertensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Brimonidine.Approved
PerospironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brimonidine.Approved
PerphenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brimonidine.Approved
PethidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brimonidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Brimonidine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Brimonidine.Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Brimonidine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brimonidine.Approved
PhenobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoxybenzamineBrimonidine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxybenzamineBrimonidine may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Brimonidine.Approved
PhenoxyethanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Brimonidine.Withdrawn
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Brimonidine.Withdrawn
PhentolamineBrimonidine may increase the hypotensive activities of Phentolamine.Approved
PhentolamineBrimonidine may increase the antihypertensive activities of Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Brimonidine.Approved, Vet Approved
PhenytoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Brimonidine.Approved
PimozideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PinacidilBrimonidine may increase the hypotensive activities of Pinacidil.Withdrawn
PinacidilBrimonidine may increase the antihypertensive activities of Pinacidil.Withdrawn
PindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PindololBrimonidine may increase the antihypertensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brimonidine.Approved
PipamperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Pipotiazine.Approved
PipotiazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Piritramide.Investigational
PiritramideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Brimonidine.Approved
PirlindolePirlindole may increase the hypotensive activities of Brimonidine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Brimonidine.Withdrawn
PivhydrazinePivhydrazine may increase the hypotensive activities of Brimonidine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Brimonidine is combined with Pizotifen.Approved
PizotifenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PolythiazideBrimonidine may increase the hypotensive activities of Polythiazide.Approved
PolythiazideBrimonidine may increase the antihypertensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Pomalidomide.Approved
PomalidomideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PractololBrimonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleBrimonidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brimonidine.Approved
PramocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brimonidine.Approved, Illicit
PrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Brimonidine.Approved
PrazosinBrimonidine may increase the antihypertensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brimonidine.Approved, Illicit, Investigational
PregabalinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Pregnanolone.Investigational
PregnanoloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Brimonidine.Approved
PrilocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Primidone.Approved, Vet Approved
PrimidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Brimonidine.Approved, Investigational, Vet Approved
ProcaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brimonidine.Approved, Vet Approved
ProchlorperazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Brimonidine.Approved, Vet Approved
PromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Promethazine.Approved
PromethazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brimonidine.Approved, Vet Approved
ProparacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Brimonidine.Approved, Investigational, Vet Approved
PropofolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Brimonidine.Approved
PropoxycaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
PropranololBrimonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
PropranololBrimonidine may increase the antihypertensive activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Brimonidine.Approved
ProtriptylineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Protriptyline.Approved
ProtriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Brimonidine.Investigational
PSD502Brimonidine may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Brimonidine.Approved, Illicit
QuazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Quetiapine.Approved
QuetiapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Quinapril.Approved, Investigational
QuinaprilBrimonidine may increase the antihypertensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Brimonidine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Raclopride.Investigational
RacloprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ramelteon.Approved, Investigational
RamelteonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Brimonidine.Approved
RamiprilBrimonidine may increase the antihypertensive activities of Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brimonidine.Approved
RasagilineRasagiline may increase the hypotensive activities of Brimonidine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brimonidine.Approved
RemifentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Brimonidine.Approved
RemikirenBrimonidine may increase the antihypertensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brimonidine.Approved, Withdrawn
RemoxiprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
RescinnamineBrimonidine may increase the hypotensive activities of Rescinnamine.Approved
RescinnamineBrimonidine may increase the antihypertensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Brimonidine.Approved
ReserpineBrimonidine may increase the antihypertensive activities of Reserpine.Approved
RilmenidineBrimonidine may increase the hypotensive activities of Rilmenidine.Investigational
RilmenidineBrimonidine may increase the antihypertensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Brimonidine is combined with Riociguat.Approved
RiociguatBrimonidine may increase the antihypertensive activities of Riociguat.Approved
RisperidoneBrimonidine may increase the hypotensive activities of Risperidone.Approved, Investigational
RisperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ritanserin.Investigational
RitanserinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RituximabBrimonidine may increase the hypotensive activities of Rituximab.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Brimonidine.Vet Approved
RomifidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleBrimonidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brimonidine.Approved
RopivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineBrimonidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Brimonidine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brimonidine.Experimental
S-EthylisothioureaBrimonidine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sacubitril.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Brimonidine.Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Brimonidine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Brimonidine is combined with Sage 547.Investigational
Sage 547Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sage 547.Investigational
SaprisartanBrimonidine may increase the hypotensive activities of Saprisartan.Experimental
SaprisartanBrimonidine may increase the antihypertensive activities of Saprisartan.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Scopolamine.Approved
ScopolamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brimonidine.Approved, Vet Approved
SecobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Brimonidine.Approved, Investigational, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Brimonidine.Approved, Investigational, Vet Approved
SelexipagBrimonidine may increase the hypotensive activities of Selexipag.Approved
SelexipagBrimonidine may increase the antihypertensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Brimonidine.Approved, Withdrawn
SertindoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brimonidine.Approved, Vet Approved
SevofluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Brimonidine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Brimonidine.Approved
SitaxentanBrimonidine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SitaxentanBrimonidine may increase the antihypertensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
SotalolBrimonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilBrimonidine may increase the hypotensive activities of Spirapril.Approved
SpiraprilBrimonidine may increase the antihypertensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Brimonidine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Brimonidine is combined with Stiripentol.Approved
StiripentolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Brimonidine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brimonidine.Approved, Investigational
SufentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brimonidine.Approved
SulpirideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SuvorexantBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TadalafilTadalafil may increase the antihypertensive activities of Brimonidine.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tandospirone.Investigational
TandospironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tasimelteon.Approved
TasimelteonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Brimonidine is combined with Telmisartan.Approved, Investigational
TelmisartanBrimonidine may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brimonidine.Approved
TemazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TemocaprilBrimonidine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemocaprilBrimonidine may increase the antihypertensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Terazosin.Approved
TerlipressinBrimonidine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerlipressinBrimonidine may increase the antihypertensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tetrabenazine.Approved
TetrabenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brimonidine.Approved, Vet Approved
TetracaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brimonidine.Investigational
TetrodotoxinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brimonidine.Approved, Vet Approved
ThiamylalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Brimonidine.Approved, Vet Approved
ThiopentalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brimonidine.Approved
ThioridazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brimonidine.Approved
ThiothixeneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tiagabine.Approved
TiagabineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Brimonidine.Approved
TianeptineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Tianeptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tiapride.Investigational
TiaprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Investigational
TiboloneBrimonidine may increase the hypotensive activities of Tibolone.Approved
TiboloneBrimonidine may increase the antihypertensive activities of Tibolone.Approved
TicrynafenBrimonidine may increase the hypotensive activities of Ticrynafen.Withdrawn
TicrynafenBrimonidine may increase the antihypertensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Brimonidine.Vet Approved
TiletamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TimololBrimonidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TimololBrimonidine may increase the antihypertensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tizanidine.Approved
TizanidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolazolineBrimonidine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolazolineBrimonidine may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brimonidine.Approved, Withdrawn
TolcaponeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Brimonidine.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Brimonidine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Brimonidine.Approved
TopiramateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Brimonidine.Approved
TorasemideBrimonidine may increase the antihypertensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Brimonidine.Approved, Investigational
TramadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Trandolapril.Approved
TrandolaprilBrimonidine may increase the antihypertensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brimonidine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.Approved
TravoprostTravoprost may increase the hypotensive activities of Brimonidine.Approved
TravoprostBrimonidine may increase the antihypertensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Brimonidine.Approved, Investigational
TrazodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Brimonidine.Approved, Investigational
TreprostinilBrimonidine may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Brimonidine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brimonidine.Approved
TriazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TrichlormethiazideBrimonidine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichlormethiazideBrimonidine may increase the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brimonidine.Approved
TrifluoperazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brimonidine.Approved, Vet Approved
TriflupromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimazosinBrimonidine may increase the hypotensive activities of Trimazosin.Experimental
TrimazosinBrimonidine may increase the antihypertensive activities of Trimazosin.Experimental
TrimethaphanBrimonidine may increase the hypotensive activities of Trimethaphan.Approved
TrimethaphanBrimonidine may increase the antihypertensive activities of Trimethaphan.Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Brimonidine.Approved
TrimipramineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Trimipramine.Approved
TrimipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brimonidine.Approved
TriprolidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Brimonidine is combined with Uc1010.Investigational
Uc1010Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Uc1010.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Brimonidine.Approved, Investigational
UnoprostoneBrimonidine may increase the hypotensive activities of Unoprostone.Approved
UnoprostoneBrimonidine may increase the antihypertensive activities of Unoprostone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Brimonidine.Approved, Investigational
Valproic AcidBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Brimonidine.Approved, Investigational
ValsartanBrimonidine may increase the antihypertensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Brimonidine.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Brimonidine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Vigabatrin.Approved
VigabatrinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VinpocetineBrimonidine may increase the hypotensive activities of Vinpocetine.Investigational
VinpocetineBrimonidine may increase the antihypertensive activities of Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brimonidine.Approved
VortioxetineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Brimonidine.Vet Approved
XylazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
XylometazolineBrimonidine may increase the hypotensive activities of Xylometazoline.Approved
XylometazolineBrimonidine may increase the antihypertensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Brimonidine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brimonidine.Approved, Illicit, Investigational
ZaleplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Ziconotide.Approved
ZiconotideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Brimonidine.Approved
ZiprasidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Brimonidine.Vet Approved
ZolazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Zonisamide.Approved, Investigational
ZonisamideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Brimonidine.Approved
ZopicloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Brimonidine.Approved
ZotepineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brimonidine.Approved, Investigational
ZuclopenthixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesD11AX21S01EA05
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (517 KB)
MSDSDownload (20.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.978
Blood Brain Barrier+0.717
Caco-2 permeable+0.5435
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor INon-inhibitor0.5688
P-glycoprotein inhibitor IIInhibitor0.5951
Renal organic cation transporterInhibitor0.8266
CYP450 2C9 substrateNon-substrate0.8403
CYP450 2D6 substrateNon-substrate0.7533
CYP450 3A4 substrateNon-substrate0.5617
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.6898
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7044
Ames testNon AMES toxic0.8222
CarcinogenicityNon-carcinogens0.9446
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0196 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8093
hERG inhibition (predictor II)Non-inhibitor0.6711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Allergan inc
  • Allergan
  • Akorn inc
  • Alcon inc
  • Alcon research ltd
  • Bausch and lomb pharmaceuticals inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Allergan, Inc
Packagers
Dosage forms
FormRouteStrength
LiquidOphthalmic0.2 %
SolutionOphthalmic0.15 %
Solution / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic1.5 mg/mL
SolutionOphthalmic1.5 mg/mL
SolutionOphthalmic2 mg/mL
Solution / dropsOphthalmic2 mg/mL
Solution / dropsOphthalmic2 mg/mg
SolutionOphthalmic
Solution / dropsOphthalmic
GelCutaneous3 mg/g
GelTopical5 mg/g
GelTopical0.33 %
SolutionOphthalmic0.2 %
SuspensionOphthalmic
Suspension / dropsOphthalmic
Prices
Unit descriptionCostUnit
Alphagan P 15ml Bottle .15% 15ml Bottle228.5USD bottle
Brimonidine Tartrate 0.15% Solution 15ml Bottle218.5USD bottle
Alphagan P 0.1% Solution 15ml Bottle208.94USD bottle
Alphagan P 10ml Bottle .15% 10ml Bottle152.32USD bottle
Brimonidine Tartrate 0.15% Solution 10ml Bottle145.65USD bottle
Alphagan P 0.1% Solution 10ml Bottle143.97USD bottle
Alphagan P 5ml Bottle .15% 5ml Bottle79.52USD bottle
Brimonidine Tartrate 0.15% Solution 5ml Bottle72.85USD bottle
Brimonidine Tartrate 0.2% Solution 10ml Bottle67.85USD bottle
Brimonidine Tartrate 0.2% Solution 15ml Bottle56.88USD bottle
Brimonidine Tartrate 0.2% Solution 5ml Bottle33.96USD bottle
Brimonidine tartrate 0.15% drp29.82USD ml
Alphagan p 0.15% eye drops14.65USD ml
Alphagan p 0.1% drops13.85USD ml
Brimonidine 0.2% eye drop6.53USD ml
Alphagan 0.2 % Solution3.72USD ml
Apo-Brimonidine 0.2 % Solution2.08USD ml
Pms-Brimonidine 0.2 % Solution2.08USD ml
Ratio-Brimonidine 0.2 % Solution2.08USD ml
Sandoz Brimonidine 0.2 % Solution2.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2173974 No2006-05-022014-09-19Canada
CA2225626 No2002-09-032016-06-17Canada
US5424078 No1995-06-132012-06-13Us
US6316441 No1999-12-072019-12-07Us
US6562873 Yes2002-01-102022-01-10Us
US6627210 Yes2002-01-182022-01-18Us
US6641834 Yes2002-01-282022-01-28Us
US6673337 Yes2002-01-262022-01-26Us
US7030149 No2002-04-192022-04-19Us
US7265117 No2005-08-192025-08-19Us
US7320976 No2002-04-192022-04-19Us
US7323463 No2003-01-192023-01-19Us
US7439241 No2005-08-252025-08-25Us
US7642258 No2002-04-192022-04-19Us
US8053427 No2011-06-132031-06-13Us
US8133890 No2002-04-192022-04-19Us
US8163725 No2011-06-132031-06-13Us
US8231885 No2005-05-242025-05-24Us
US8354409 No2002-04-192022-04-19Us
US8410102 No2005-05-242025-05-24Us
US8426410 No2005-05-242025-05-24Us
US8513247 No2011-03-252031-03-25Us
US8513249 No2011-03-252031-03-25Us
US8748425 No2002-04-192022-04-19Us
US8858961 Yes2004-03-022024-03-02Us
US8859551 No2004-05-252024-05-25Us
US9044484 No2010-10-302030-10-30Us
US9295641 No2001-07-102021-07-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point207.5 °CNot Available
water solubilitySoluble (1.5 mg/mL)Not Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.154 mg/mLALOGPS
logP1.27ALOGPS
logP1.37ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.2 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.49 m3·mol-1ChemAxon
Polarizability25.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinoxalines
Direct ParentQuinoxalines
Alternative Parents
Substituents
  • Quinoxaline
  • 2-bromoaniline
  • Benzenoid
  • Pyrazine
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • 2-imidazoline
  • Guanidine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Rauly I, Ailhaud M, Wurch T, Pauwels PJ: alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. [PubMed:10799649 ]
  2. Wikberg-Matsson A, Simonsen U: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. [PubMed:11481271 ]
  3. Meana JJ, Barturen F, Garro MA, Garcia-Sevilla JA, Fontan A, Zarranz JJ: Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J Neurochem. 1992 May;58(5):1896-904. [PubMed:1373179 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11. [PubMed:14610637 ]
  2. Bohmann C, Schollmeyer P, Rump LC: Methoxamine inhibits noradrenaline release through activation of alpha 1- and alpha 2-adrenoceptors in rat isolated kidney: involvement of purines and prostaglandins. Naunyn Schmiedebergs Arch Pharmacol. 1993 Mar;347(3):273-9. [PubMed:8097565 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11. [PubMed:14610637 ]
  2. Orito K, Kishi M, Imaizumi T, Nakazawa T, Hashimoto A, Mori T, Kambe T: alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator. Br J Pharmacol. 2001 Oct;134(4):763-70. [PubMed:11606316 ]
  3. Zhang W, Ordway GA: The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res. 2003 Apr 10;112(1-2):24-32. [PubMed:12670699 ]
  4. Prinster SC, Holmqvist TG, Hall RA: Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther. 2006 Sep;318(3):974-81. Epub 2006 Jun 6. [PubMed:16757535 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine dehydrogenase activity
Specific Function:
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:
AOX1
Uniprot ID:
Q06278
Molecular Weight:
147916.735 Da
References
  1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, Tang-Liu D: Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica. 1996 Oct;26(10):1035-55. [PubMed:8905918 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 03:55